Clinical Trial Results: Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers [Phase 2]

View source ↗

Summary

Phase 2 trial of nivolumab for recurrent rare CNS cancers (including medulloblastoma and ependymoma) was terminated with results posted in 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Malignant Meningioma
• Choroid Plexus Tumors
• Ependymoma
• Medulloblastoma
• Pineal Region Tumors

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Medulloblastoma, Ependymoma | Phase 2 | Status: TERMINATED | Results posted: 2026-08-18